Navigation Links
Hypogonadism in Medical News

New recommendations by scientific societies about late-onset hypogonadism

Arnhem, 04 December 2008 The January issue of European Urology , the official journal of the European Association of Urology published by Elsevier, will feature new recommendations on late-onset hypogonadism (LOH), recently formulated by major scientific organizations. LOH is a clinical and bioc...

QuatRx Announces Further Positive Phase 3 Results For Ophena(TM) (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy

...cal program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel ...

Men with Low Testosterone See Multiple Doctors Before Being Diagnosed; Many Dissatisfied with Current Treatment Options

... Although testosterone levels decline with age, hypogonadism is not a natural consequence of the aging process. "Men with clinically diagnosed hypogonadism do not need to 'tolerate' the symptoms of low test...countries by Bayer Schering Pharma AG. ABOUT hypogonadism Hypogonadism, also known as low testosterone...

Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show

...ased new long-term clinical trial data in men with hypogonadism who were treated for 21 months with testosterone u...rology at Harvard Medical School . "But treating hypogonadism can result in significant health benefits for pati.... Morgentaler noted: "Because men who suffer from hypogonadism need to remain on treatment for life, it is very i...

Pharmacyclics Announces Dr. Ahmed Hamdy as New Chief Medical Officer

... 2004, Dr. Hamdy was a Senior Principal Scientist at Watson Pharmaceuticals where he participated in an ANDA for testosterone gel for the treatment of hypogonadism that was approved 2005. He also participated in multiple INDs in oncology and autoimmune diseases leading to successful phase I and phase II programs...

Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals

...tly markets products to treat overactive bladder, prostate cancer and central precocious puberty and is pursuing regulatory approval of drugs to treat hypogonadism and bladder cancer. Mr. Holveck noted, "In addition to the very successful drug, VANTAS(R), we are particularly excited about the opportunity to ...

JCI online early table of contents: July 1, 2008

...d and colleagues, at Massachusetts General Hospital, Boston, has identified mutations in the FGF8 gene in individuals with idiopathic hypogonadotropic hypogonadism (IHH), a disease characterized by failed sexual maturation and infertility due to a deficiency in the small protein gonadotropin-releasing hormone (Gn...

FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus

...ights to NEBIDO from Bayer Schering Pharma AG, Germany in July 2005. About hypogonadism Male hypogonadism is an increasingly recognized medical condition characterized by a reduced ...

Low Serum Testosterone Levels Associated With Fall Risk in Elderly Men

... Prolonged hypogonadism may result in erectile dysfunction, decreased libido, anemia, sarcopenia, m...ne level is well-known for its association with osteoporosis, the impact of hypogonadism on overall physical functioning and fall risk has not been prospectively ev...

Detrimental Effect Of Chronic Alcoholism On Male Fertility

...ht cause gonadal disorders, including structural testicular changes and a decrease in testicular and serum levels of T, which might be involved in the hypogonadism and feminization phenotype. A reduction in sperm concentration and in the percentage of spermatozoa with normal morphology has been detected in ch...
Hypogonadism in Medical Technology

Repros' Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 5, 2007 - Repros Therapeutics Inc. (NasdaqGM:RPRX) announced topline results of a six month U.S. Phase 3 study of Androxal(TM), an oral drug being developed to restore normal testicular function in men with secondary hypogonadism. Further, Androxal demonst...

QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy

...preclinical program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 as an oral treatment for the symptoms of secondary hypogonadism and other conditions in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. Be...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

...tners in Europe and other territories. About hypogonadism Male hypogonadism is an increasingly recognized medical condition ch...icantly impair quality of life. Common effects of hypogonadism include decreased sexual desire, erectile dysfunct...

QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy

...cal program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for dyslipidemia. Asord(TM) (beco...

QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome

...cal program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel ...

Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome

...aged 40-69 years, it is estimated that there are about 481,000 new cases of hypogonadism per year. Overall, approximately 2.4 million U.S. men suffer from the condition.(1) hypogonadism results from a deficiency in testosterone secretion that may occur naturall...

Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy

...cal program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for dyslipidemia. Asord(TM) (beco...

Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture

...ts, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. XIAFLEX(TM) (clostridial collagenas...

QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy

...cal program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for dyslipidemia. Asord(TM) (beco...

Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association

...been previously announced, are based on a Phase III study in which men with hypogonadism and low serum testosterone levels prior to entering the study were treated ...Bayer Schering Pharma AG, Germany in July 2005. About Hypogonadism Male hypogonadism is an increasingly recognized medical condition characterized by a reduced ...
Hypogonadism in Medical Definition

Pathology

...- Adrenal insufficiency ( Addison's disease ) - Hypoaldosteronism Gonads Polycystic ovary syndrome - 5-alpha-reductase deficiency - hypogonadism - Delayed puberty - Precocious puberty Other Autoimmune polyendocrine syndrome - Carcinoid syndrome - Laron syndrome - Psychogenic...
Hypogonadism in Medical Dictionary

Hypogonadism

Hypogonadism is a medical term for a defect of the reproductive system that results in lack of function of the gonads . The gonads have two functions: to produce hormones, activin and to produce gametes (eggs or sperm). Deficiency of sex hormones can result in defective... Male hypogonadism ...

Uremia

...ia affecting many systems of the body, ... ... like renal failure resulting in uremia in males is associated with decreased ... The cause of hypogonadism in uremia is probably multifactorial. ... ...
Hypogonadism in Biological News

Study identifies pathway required for normal reproductive development

... of Medicine. The current study is the latest in a series of investigations by the MGH group into the genetic basis of idiopathic hypogonadotropic hypogonadism (IHH), a rare condition in which puberty does not take place naturally. IHH occurs when a structure in the brain called the hypothalamus fails to dev...

New licensing agreement to maximize AIDS drug development

...ngapore and South Korea. FortigelTM (testosterone gel), branded Tostrex® outside the United States, is marketed in Sweden for the treatment of male hypogonadism also by ProStrakan. Approvals of Rectogesic and Tostrex by the other member states of the European Union are being sought through the Mutual Recogni...
Hypogonadism in Biological Technology

QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference

...nt programs. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. QRX-431, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for lipid disorders and obesity. Aso...
Hypogonadism in Biological Definition

Infertility

...oblems, i.e. diabetes mellitus , thyroid disorders Hypothalamic disorders, i.e. Kallmann syndrome Hyperprolactinemia Hypopituitarism hypogonadism due to various causes Psychological factors Drugs, alcohol Testicular factors Genetic causes, e.g. Klinefelter syndrome Neoplasm, e.g....
Other Tags
(Date:7/13/2014)... According to a new market research ... Component (processor, GPU, DSP, connectivity), Technology Node (45nm-5nm), ... - Forecast and Analysis to 2014-2020", published by ... Market is expected to reach $61.70 Billion by ... 2014 to 2020. , Browse 71 market data ...
(Date:7/13/2014)... Serena Gordon HealthDay ... A new type of sensor for people with diabetes ... using saliva instead of blood, researchers report. Scientists at ... tested it using artificial saliva. It uses light, metal and ... sugar. "Everybody knows that diabetics have to prick their ...
(Date:7/13/2014)... 13, 2014 The federal court overseeing ... filed against Johnson & Johnson’s Ethicon, Inc. is ... is expected to get underway next month. According to ... District Court, Southern District of West Virginia on July ... August 7, 2014 at 3:00 p.m. July selection is ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular ... has released its new range of elegant Quinceanera ... available at discounted prices. Worldwide clients can enjoy this ... the company’s online shop, there are plenty of beautiful ... with great materials. MyDressCity.com’s hot items are prom gowns, ...
(Date:7/13/2014)... A noninvasive optical imaging device developed at ... later occur in the brain and are a ... results from investigators conducting a clinical trial in ... July 15 in an oral presentation at the ... They also were invited by conference organizers to ...
Breaking Medicine News(10 mins):Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
(Date:7/11/2014)... brains of all vertebrates, information is transmitted through ... chemical signal to be passed from one brain ... most abundant type of synapse, can be either ... learning, memory, perception and cognition, and the balance ... function. For instance, every time we learn ...
(Date:7/10/2014)... June 30, 2014  Aware, Inc. (NASDAQ: ... services, previously announced on June 26, 2014 that its ... of $1.75 per share, or approximately $40 million in ... 10, 2014 and a payment date of July 24, ... it had set an ex-dividend date for this special ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
Other Contents